United States Patent 6,124,304: Scope of Claims, Claim Strength, and US Landscape for Zoster Pain and PHN

US Patent 6,124,304 claims method-of-treatment use of famciclovir and penciclovir for zoster-associated pain (ZAP) and prophylactic post-herpetic neuralgia (PHN), with time-from-rash cutoffs, duration, age gating, and dose-frequency alternatives for famciclovir. The patent’s scope is therefore anchored to (i) the active molecules and (ii) method parameters that narrow infringement risk to specific initiation timing, treatment length, patient age bands, and dosing regimens.

What is the claimed invention and how is infringement framed?

Core claim structure (what must be met)

Each independent claim is a method claim that requires all of the following elements:

Condition: a human “in need” of treatment for either:
- Zoster-associated pain (ZAP), or
- Prophylactic treatment of post-herpetic neuralgia (PHN).
Therapeutic agent (fixed by the claims):
- Famciclovir (compound name: “9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-aminopurine”), or its pharmaceutically acceptable salt, for ZAP and prophylactic PHN.
- Penciclovir (compound name: “9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine”), or its pharmaceutically acceptable salt, for ZAP and prophylactic PHN.
Method parameters are claimed in dependent claims:
- initiation timing relative to rash onset (72 hours, 48 hours),
- treatment duration (7 days),
- patient age thresholds (>50, >60, >70),
- famciclovir dose and frequency patterns,
- and for penciclovir, route: topical vs parenteral.

Infringement by performance, not formulation

No claim is directed to composition, manufacturing process, or formulation composition other than “pharmaceutically acceptable salt.” Enforcement is tied to what a clinician does: selecting the drug and administering it in a regimen that satisfies dependent claim limitations.

Independent claim coverage

From the text supplied:

Claims 1-12: ZAP method with famciclovir; dependent limitations include initiation within 72h/48h, 7-day treatment, age bands, and multiple dose-frequency options.
Claims 13-24: prophylactic PHN method with famciclovir; same dependent structure but “prophylactic” framing.
Claims 25-42: ZAP and prophylactic PHN methods with penciclovir; dependent limitations include initiation windows, 7-day duration, age bands, and route.

How broad are the claim limits on drug, timing, duration, age, dose, and route?

Drug scope

The chemical identity is narrow:

Drug in claim	Claim categories	Claimable scope notes
Famciclovir (9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-aminopurine)	ZAP (1-12) and prophylactic PHN (13-24)	Covers “famciclovir” and “pharmaceutically acceptable salt thereof”
Penciclovir (9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine)	ZAP (25-32) and prophylactic PHN (35-42)	Covers “penciclovir” and “pharmaceutically acceptable salt thereof”

Timing scope (initiation windows)

Dependent claim limitations explicitly narrow treatment initiation relative to rash onset:

within 72 hours (claims 2, 14, 26, 36)
within 48 hours (claims 3, 15, 27, 37)

This creates a sliding enforcement boundary: initiation later than 72 hours avoids dependent claim coverage but may still fall under independent claims if the independent claims are asserted without those limitations.

Treatment duration

A single explicit duration appears:

7 days (claims 4, 16, 28, 38)

Age gating

Age bands are sequentially dependent:

>50 years (claims 5, 17, 29, 39)
>60 years (claims 6, 18, 30, 40)
>70 years (claims 7, 19, 31, 41)

These are not additive in independent form; they become limiting only in dependent assertions.

Route limitations for penciclovir

Penciclovir has route-specific dependent claims:

topical administration (claim 32) for ZAP
parenterally administered (claim 34) for ZAP
parenterally administered (claim 42) for prophylactic PHN

So topical penciclovir is claimed only within the ZAP set via claim 32; prophylactic PHN via penciclovir is claimed with parenteral route via claim 42.

Dose and frequency options for famciclovir

Famciclovir has a broad dependent dose-frequency matrix (one dose range with multiple schedule variants):

Claim 8: famciclovir administered at 250 mg, 500 mg, or 750 mg, twice or three times a day (ZAP)
Claim 9: 250 mg three times a day (ZAP)
Claim 10: 500 mg three times a day (ZAP)
Claim 11: 500 mg twice a day (ZAP)
Claim 12: 750 mg once a day (ZAP)

For prophylactic PHN:

Claim 20: famciclovir administered at 250 mg, 500 mg or 750 mg once, twice or three times a day (PHN prophylaxis)
Claim 21: 250 mg three times a day (PHN)
Claim 22: 500 mg three times a day (PHN)
Claim 23: 500 mg twice a day (PHN)
Claim 24: 750 mg once a day (PHN)

This is an important scope feature: the dose-frequency limitations are expressed as alternative dependent claims, making it easier to find an accused regimen that maps onto one of the listed schedules.

What is the legal and commercial coverage split: ZAP vs PHN prophylaxis?

ZAP claims vs prophylactic PHN claims

The patent separates:

ZAP treatment (claims 1-12, 25-33)
PHN prophylactic treatment (claims 13-24, 35-42)

This split matters because clinical practice and labeling may distinguish:

antiviral use to treat acute herpes zoster and
antiviral effect on later PHN risk.

Even where a regimen is identical, enforcement risk depends on whether a method is performed with the purpose of “prophylatic treatment” of PHN versus treatment of ZAP symptoms.

Same regimen scaffold, different outcome framing

The dependent limitations (timing, 7 days, age, dosing, route) mirror across ZAP and prophylactic PHN sets, but the objective is tied to:

“treatment of zoster associated pain” vs
“prophylatic treatment of post-herpetic neuralgia.”

Where are the claim “squeeze points” that narrow infringement?

Dependent claim add-ons create carve-out possibilities

The dependent limitations create factual “switches” that can reduce infringement if an accused regimen misses one required feature.

For example, under dependent claim coverage for ZAP with famciclovir:

initiation must be within 72h or 48h (claims 2-3),
duration must be 7 days (claim 4),
and/or the patient must be >50 / >60 / >70 (claims 5-7),
with a matching dose-frequency option (claims 8-12).

If an accused regimen differs in any of these features, dependent claim coverage can fail, though independent claims may still be asserted.

Route as a discriminator for penciclovir

For penciclovir, route can be decisive:

topical penciclovir is explicitly claimed only for ZAP (claim 32),
parenteral penciclovir is explicitly claimed for both ZAP (claim 34) and prophylactic PHN (claim 42).

How does this patent sit within the US patent landscape for famciclovir and penciclovir indications?

Functional landscape positioning

US 6,124,304 is a method-of-use patent centered on:

known antiviral nucleoside analogs (famciclovir is a prodrug of penciclovir in clinical pharmacology),
and an outcome/indication frame around ZAP and prophylactic PHN.

In US practice, this kind of claim often lives alongside:

earlier chemical and composition patents for the active ingredients, and
later “new use” or “dose/timing/population” patents.

Landscape leverage and typical challenges

Method-of-use patents for known drugs typically face:

anticipation or obviousness risks based on prior clinical literature and earlier filings describing antiviral use for herpes zoster complications,
and claim construction disputes around what constitutes “zoster associated pain” and whether “prophylatic treatment” requires specific clinical endpoints or timing logic beyond prescribing.

This claim set mitigates some enforcement friction by:

specifying time-from-rash onset thresholds,
specifying 7-day duration,
specifying age thresholds, and
specifying dose-frequency alternatives for famciclovir. Those features make it easier to map a clinical protocol to a dependent claim.

Claim-by-claim scope map (what each dependent claim narrows)

Famciclovir ZAP (claims 1-12)

Claim	Adds limitation to claim 1	Scope impact
2	start within 72 hours of rash onset	Narrows initiation window
3	start within 48 hours of rash onset	Narrows initiation window further
4	treatment period is 7 days	Narrows duration
5	patients >50 years	Narrows population
6	patients >60 years	Narrows further
7	patients >70 years	Narrows further
8	dose: 250/500/750 mg, twice or three times/day	Narrows dose-frequency set
9	250 mg three times/day	Narrows to single schedule
10	500 mg three times/day	Narrows to single schedule
11	500 mg twice/day	Narrows to single schedule
12	750 mg once/day	Narrows to single schedule

Famciclovir prophylactic PHN (claims 13-24)

Claim	Adds limitation to claim 13	Scope impact
14	start within 72 hours	Narrows initiation
15	start within 48 hours	Narrows initiation further
16	treatment period 7 days	Narrows duration
17	patients >50 years	Narrows population
18	patients >60 years	Narrows population
19	patients >70 years	Narrows population
20	dose: 250/500/750 mg once, twice or three times/day	Broad dose-frequency dependency set
21	250 mg three times/day	Narrows to one schedule
22	500 mg three times/day	Narrows to one schedule
23	500 mg twice/day	Narrows to one schedule
24	750 mg once/day	Narrows to one schedule

Penciclovir ZAP (claims 25-34)

Claim	Adds limitation to claim 25	Scope impact
26	start within 72 hours	Narrows initiation
27	start within 48 hours	Narrows initiation further
28	treatment period 7 days	Narrows duration
29	patients >50 years	Narrows population
30	patients >60 years	Narrows further
31	patients >70 years	Narrows further
32	penciclovir administered topically	Adds route discriminator
33	compound is sodium salt of penciclovir	Limits salt form
34	compound administered parenterally	Adds route discriminator

Penciclovir prophylactic PHN (claims 35-42)

Claim	Adds limitation to claim 35	Scope impact
36	start within 72 hours	Narrows initiation
37	start within 48 hours	Narrows initiation further
38	treatment period 7 days	Narrows duration
39	patients >50 years	Narrows population
40	patients >60 years	Narrows further
41	patients >70 years	Narrows further
42	compound administered parenterally	Adds route discriminator

How should business teams use these claims for freedom-to-operate (FTO) and launch planning?

Protocol mapping approach

For any candidate protocol for famciclovir or penciclovir in US:

identify whether the clinical intent fits:
- “ZAP treatment” or
- “prophylatic treatment of PHN”
map initiation timing to:
- ≤72 hours and/or ≤48 hours from rash onset
map duration to:
- 7-day course
map patient age to:
- 50, >60, or >70
map dose-frequency to:
- the discrete schedule alternatives in claims 9-12 (ZAP) or 21-24 (PHN) for famciclovir
map route to:
- topical vs parenteral for penciclovir, as claimed.

Key commercial insight: dose-frequency alternatives reduce design-around space

For famciclovir, the dependent claims list multiple common dosing patterns:

250 mg TID,
500 mg TID,
500 mg BID,
750 mg QD, plus broader “twice or three times/day” (ZAP) and “once, twice or three times/day” (PHN) constructs.

That structure makes it harder to avoid claim coverage via small schedule changes.

Key Takeaways

US 6,124,304 is a method-of-use patent that enforces on antiviral administration for ZAP and prophylactic PHN, anchored to famciclovir and penciclovir.
Dependent claims narrow enforcement using time-to-treatment (72h and 48h), course length (7 days), age thresholds (>50/>60/>70), and for famciclovir also dose-frequency schedules.
Penciclovir claims add route specificity: topical (ZAP) and parenteral (ZAP and prophylactic PHN), plus a salt limitation (sodium salt of penciclovir).
Claim architecture uses multiple alternative dependent limitations, which can make it easier for enforcement to match an accused regimen to at least one dependent claim even if not all limitations are shared.

FAQs

1) Does the patent cover both treatment and prevention of PHN?

Yes. It has separate claim groups for ZAP treatment and prophylatic PHN treatment, each tied to famciclovir or penciclovir.

2) What timing elements matter most for enforcement under the dependent claims?

The dependent claim limits include starting therapy within 72 hours or within 48 hours of rash onset.

3) Is the course length constrained?

Yes. Dependent claims recite a 7-day treatment period.

4) What patient selection constraints appear in the claims?

Dependent claims gate on age bands: greater than 50, greater than 60, and greater than 70 years.

5) How do dosing claims affect design-around for famciclovir?

Dependent claims list multiple dosing schedules (including 250 mg TID, 500 mg TID, 500 mg BID, and 750 mg once daily), and broader dose-frequency language, which reduces flexibility to avoid mapping to at least one schedule.

References

[1] US Patent 6,124,304 (claim text provided in prompt).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9320485	Oct 05, 1993
United Kingdom	9321255	Dec 14, 1993
United Kingdom	9326177	Dec 22, 1993

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	616	⤷ Start Trial
African Regional IP Organization (ARIPO)	9400684	⤷ Start Trial
Austria	216885	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 6,124,304